STUDresearch · Peptide
Thymalin
Also known as
Thymic bioregulator · Thymus polypeptide complex · Thymalinum · Thymalin (calf thymus extract) · Thymus polypeptide fraction · KEW peptide complex (discussion) · Khavinson thymic complex · CAS 79621-14-0 (complex preparation, discussion)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Some talk
Systemic
IM / SubQ / Oral
Longevity & bioregulators
Systemic — multi-peptide thymic bioregulator framed for immune, blood-cell, and age-related immune regulation, not a local soft-tissue injury agent.
What people say
Thymalin is a calf-thymus polypeptide complex used in Russian immunocorrection literature and longevity-community courses. It is not one defined sequence or interchangeable with TA-1, Thymogen or thymulin.
Doses people talk about
Route transfer is not proven, and this animal-derived mixture is not dose-equivalent to defined thymic peptides or oral products.
How it may feel
Many notes describe little acute sensation. One illness-context poster reported remaining active and keeping appetite as fever and runny nose resolved, while another commenter reported a day-four migraine-like headache.
Community route-transfer band~5–10 mg SubQ or IM once daily
Community charts reuse similar milligram amounts across routes without a bioequivalence package.
Single-person illness-context account1 mg daily for 2 weeks, then 3 mg daily for 5 days
The reporter did not specify route in the visible post and changed amount after symptoms began; this was not a controlled infection study.
Clinical-literature band~5–10 mg IM once daily
Usually described as a short consecutive course in Russian clinical literature.
Half-life & effect duration
- Half-life in the body
- Thymus peptide mixtureNo single half-life
- Felt duration people report
- One illness-course accountFever and runny nose resolved while cough remained
- Another accountMigraine-like headache on day 4
Cycles people discuss
Public discussion favors short 5–10-day courses with months between runs, often paired with pineal-peptide calendars. Multi-year longevity claims concern repeated courses, not one injection block.
Timing
Once-daily morning or early-evening use is described by convenience, with some Epitalon stacks split by clock. No single mixture half-life or depot curve was established.
Stacks
Epitalon is the classic pairing; Vilon, Thymogen, TA-1 and other bioregulators are also compared or sequenced. Combined-course stories cannot isolate Thymalin's contribution.
Watch for
Source / extract risk: Gray-market animal-derived thymus extracts risk contamination, endotoxin, mislabeling, and batch composition drift.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No single human plasma half-life can be assigned to Thymalin as a multi-peptide calf-thymus extract.
The inspected review describes Thymalin as a polypeptide complex isolated from calf thymus and discusses short active fragments, but does not provide a mixture concentration-time curve or component-specific human clearance.
No universal absence is claimed: the reviewed originator paper is not a comprehensive pharmacokinetic search, and different extract batches may contain different components.
- Khavinson et al.: The use of Thymalin for immunocorrection and molecular aspects of biological activity (opens in a new tab)Full article inspected, especially the introduction and discussion identifying Thymalin as a polypeptide complex isolated from calf thymus and describing the originator-line immune and short-peptide mechanism claims; no human concentration-time PK section was present.Originator-line narrative review, not an independent PK study; lack of PK in this article is not proof that no inaccessible data exist.
Felt duration people report
No per-dose felt window was established; the clearest report describes an illness course over weeks, not onset and offset from one administration.
One poster described 1 mg daily for two weeks, then 3 mg daily for five days after a chest cold began, with fever and runny nose resolving while cough remained. Another commenter mentioned a migraine-like headache on day four.
Unverified product and route, active infection, changing amount and no control; a week-long cold can resolve without the compound and the headache came from a different author.
- Thymalin experience (opens in a new tab)Read the complete visible archived thread: Tenzky's 1 mg daily for two weeks then 3 mg daily for five illness days, no reported injection-site effects, fever/runny-nose resolution with residual cough, continued activity and appetite; the author's follow-up comparing TA-1/thymulin; Jomobirdsong's combined TA-1 year plus Thymalin month; and muratgendigelen's day-four migraine-like headache.Multiple authors and products, no route verification, concurrent illness and combined-peptide use; accounts do not establish efficacy, incidence or a per-dose duration.
What people say
- Longevity stacks: Paired with pineal peptides (epithalamin / Epitalon) for annual or twice-yearly “immune + pineal” tune-ups in community and clinic marketing. forum
- Post-viral / convalescence: Anecdotes of less lingering fatigue or easier bounce-back after a short course — heavily confounded by rest and co-interventions. anecdote
- Infection-season resilience: Fewer colds or shorter URIs claimed after seasonal courses; expect high lifestyle confounding. forum
- Vs Thymogen alone: Some forum takes prefer Thymogen (EW) for “cleaner” immune feel or less fatigue; others prefer full Thymalin complex as the “complete” thymus extract — pure preference lore without controlled comparison. forum
- T-cell / lymphocyte labs: Clinical and community narratives claim lymphocyte or T-cell marker normalization over short courses; COVID-adjunct work reported faster recovery from lymphopenia and NK-cell count improvements vs standard care alone in one older-patient trial. trial
- COVID-adjunct mortality signal (single-center): Severe COVID older-patient report (10 mg IM daily × 10 days + standard therapy) described faster CRP/D-dimer/lymphocyte normalization and lower hospital mortality vs control arm — design limitations apply; not a Western multi-center confirmation. trial
- Older adults / geroprotection: Multi-year Russian elderly cohorts (often Thymalin ± epithalamin) are cited for mortality and healthspan signals; English and Russian write-ups of the same ~266-subject lineage are not independent replications. trial
- Blood-forming / coagulation-adjacent talk: Research summaries mention hematopoiesis-adjacent immune regulation and older notes on cell-mediated immunity and coagulation parameters in complex therapy — not a modern anticoagulant claim. trial
- Vs Thymosin Alpha-1 (bro framing): Thymalin framed as broader thymic-complex / “regeneration + regulation” bioregulator; TA-1 framed as defined single-peptide immune modulator with stronger Western/clinical-trial brand recognition — head-to-head RCTs are not the community’s evidence base. forum
- Feel: Little acute stimulant, pump, or GH-like “on” sensation — quieter resilience and lab/seasonal framing. forum
- What it is not proven for (honest gap): No high-quality Western evidence that it prevents serious infection, extends human lifespan, replaces vaccines/antivirals, or treats autoimmunity as a primary therapy. trial
- Immune dysfunction framing: Originator and Russian clinical literature position Thymalin for immune dysfunction, viral/bacterial infection adjunct settings, and regeneration-adjacent immunocorrection. trial
Doses people talk about
- Most-cited community adult band: ~5–10 mg once daily SubQ or IM for ~5–10 days — mirrors clinical mg even when route shifts to SubQ. forum
- Lower maintenance / anti-aging talk: ~5 mg/day for 5–10 days as a lighter longevity course in protocol guides. forum
- Higher end of charts: ~10 mg/day × ~10 days is the “standard full course” number repeated by clinics and blogs (including popular longevity writers citing ~5–10 mg IM/SubQ × 10 days). forum
- Community SubQ course totals: Roughly ~5–20 mg/day ranges appear in research-chem writeups; some aggregate “per course” language is looser than daily mg × days — read charts carefully. forum
- Alternative / advanced community protocols (not trial-validated): Immune-prep ~5 mg/day × ~5 days before cold/flu season; longer low-intensity ~5 mg 3×/week for ~3–4 weeks in older or post-illness narratives; longevity stack concurrent with Epitalon ~2×/year. forum
- Minority “0.5–5 mg/day” anti-aging blogs: Some secondary wellness posts list lower daily bands — minority vs the 5–10 mg clinical echo; provenance often thin. forum
- Oral / cytogen-style forms: Oral thymic bioregulators and cytogen capsules are discussed as a related category; there is no clean mg equivalence to injectable pharmaceutical Thymalin courses. forum
- Route dose transfer caution: Published human dose evidence is overwhelmingly IM; SubQ community practice reuses similar mg without a bioequivalence package. forum
- Vendor / identity flag: Research-vial potency and peptide fingerprint may not match pharmaceutical Thymalin; batch variance is a first-class uncertainty. forum
- Course length (literature + charts): Daily for ~5–10 consecutive days; some cites span ~3–10 days. trial
- COVID-adjunct example: 10 mg in 2 mL 0.9% NaCl IM daily × 10 days on top of standard therapy in one severe COVID older-patient study. trial
- Geroprotection / multi-year cohort patterns (originator lineage): Examples include 10 mg IM daily × 10 days (100 mg per course); alternate schedules with 10 mg × 5 doses at 2–3 day intervals (50 mg per course) and ~5–6 month gaps; combined Thymalin + epithalamin arms at 10 mg each × 10 days annually for multiple years in small groups. trial
- Framing: Discussed research and community ranges only — not advice, not a prescription, not FDA-labeled dosing. forum
- Core clinical-literature band (Russian IM practice): ~5–10 mg once daily intramuscular for a short consecutive course. trial
- Wider historical band: ~1–20 mg/day appears across indications and secondary summaries of historical inserts; not every figure is a modern RCT arm. trial
How it may feel
- Days 1–3: Little subjective change for many; mild injection-site awareness, occasional short-lived fatigue or flu-like “immune activation” notes in minority logs. forum
- Days 4–19 in one illness-context report: One poster described 1 mg daily for two weeks before a chest cold, then 3 mg daily after symptoms began; five days later fever and runny nose had resolved while cough remained, and the poster reported staying active with appetite intact. A week-long cold is not unusual, so causality was not established. anecdote
- End of 5–10 day block: Most “acute course” sensation ends with the last injection; subjective wins are often subtle or delayed. forum
- Weeks 2–4 post-course: Common window where community judges fewer colds, easier recovery, or retests CBC/lymphocyte panels if they track labs. forum
- Months 2–6 off: Quiet maintenance between scheduled courses; continuous daily use is not the dominant culture. forum
- Seasonal / annual re-runs: Hard to credit benefit without baselines until the next illness season or next lab draw. anecdote
- No change after 1–2 courses: Forums reassess sleep, stress, product identity (extract vs wrong label), expectations, and whether goals were lab- vs feel-based before chasing higher mg. forum
- Multi-year longevity framing: Originator geroprotection narratives emphasize repeated courses over years, not one 10-day hero cycle. trial
Cycles people discuss
- Standard course block: ~5–10 consecutive daily injection days, then stop. forum
- Classic rest between courses: ~1–6 months off; many charts land on ~every 3–6 months or ~every 6–12 months. forum
- Yearly load: Often ~1–4 courses/year depending on age, stress, or immune-season goals — not open-ended daily forever. forum
- Longevity / Khavinson-style cadence: Annual or twice-yearly immune courses, frequently calendar-aligned with pineal peptide courses. forum
- Seasonal timing: Some re-run before winter or after a hard infection season. anecdote
- Not continuous: Pulsed short courses dominate public logs and originator practice summaries more than chronic daily injection. forum
- Judge horizon: Feel/illness resilience over weeks–months post-course; longevity claims if judged at all are multi-year and confounded. forum
- Geroprotection literature pattern: Strongest originator mortality narratives came from courses repeated over multiple years (e.g., annual combined courses or multi-year bioregulation programs), not a single 10-day block. trial
Timing
- Why short courses anyway: Practice aims at regulatory / immune-cell / gene-expression effects that may outlast circulating peptide, not steady-state blood levels like a long-acting hormone. forum
- Injection timing: Once daily is the default; morning or early evening by convenience — no stimulant peak-performance clock. forum
- Stack split timing (optional lore): Some concurrent Epitalon stacks put Thymalin morning and Epitalon evening to separate attribution — preference, not PK proof. forum
- No depot narrative: Unlike long-acting GH secretagogues, users do not dose around a multi-day half-life curve. forum
- Half-life honesty: Multi-peptide extract — no single validated modern human plasma half-life for “Thymalin” as one molecule; components are short peptides expected to clear quickly via peptidases. trial
- After clearance: Literature and community both frame possible immune-cell or marker changes continuing post-course. trial
More on what it is
- Why people search it: Longevity and immune-peptide niches want age-related immune decline support, infection-resilience courses, and the classic Thymalin + pineal (Epitalon/epithalamin) annual pair. forum
- Gray-market flag: Research vials labeled “Thymalin” can vary in composition and potency vs pharmaceutical registered product; independent COAs are not guaranteed. forum
- What it is: Pharmaceutical-style bovine (calf) thymus polypeptide complex from Soviet/Russian immunocorrection research — a multi-fraction extract, not one fixed amino-acid sequence. trial
- Active short peptides discussed inside it: Dipeptides KE (Lys-Glu / Vilon) and EW (Glu-Trp / Thymogen), plus tripeptide EDP (and other low-MW fractions) are the components originator papers highlight. trial
- In-vitro cytokine signal: KE/EW components reduced IL-1β, IL-6, and TNF-α synthesis ~1.4–6× in LPS-stimulated human PBMCs in a 2023 originator-adjacent paper — cell work, not a dosing recipe. lab
- HSC marker signal: Originator-line culture work reported large increases in T-cell maturation marker CD28 on human hematopoietic stem cells — again in vitro, not a clinical proof package. lab
- Evidence posture: Decades of Russian/Eastern European clinical use and originator reviews; COVID-adjunct and older geroprotection cohorts exist; large modern Western longevity RCTs and independent pharmacovigilance are largely absent. trial
- Not the same as (name traps): Thymosin Alpha-1 (defined 28-aa synthetic), thymulin/FTS (zinc-dependent nonapeptide), Thymogen alone (EW dipeptide drug), Thymosin Beta-4 / TB-500, or synthetic Vilon alone — dose charts do not transfer. trial
- Mechanism talk: Immunomodulation of T-cell differentiation/proliferation, reduced lymphocyte apoptosis in models, cytokine-balance and hematopoiesis-adjacent framing; short peptides are claimed to interact with DNA/histones and gene expression (Khavinson-line narrative). trial
Stacks
- Top stack — Thymalin + Epitalon (or epithalamin/pineal peptides): Classic “Soviet longevity” pair: thymic complex + pineal bioregulator. forum
- Concurrent course numbers (as discussed): Thymalin ~5–10 mg daily + Epitalon commonly ~5–10 mg daily (or lower community Epitalon charts) over the same ~10–20 day window; some split morning Thymalin / evening Epitalon. forum
- Broader Khavinson / cytomedine sets: Rotated or sequenced with Vilon, Thymogen, Pinealon, Cartalax, Vesugen, Cortagen, and other organ bioregulators in multi-course annual plans. forum
- Thymic class sequencing: Compared or sequenced with Thymosin Alpha-1 more often than co-injected daily; some run TA-1 for “acute immune” blocks and Thymalin for yearly bioregulator blocks. forum
- Vilon / Thymogen substitution talk: Users sometimes swap synthetic KE or EW for extract Thymalin when seeking defined molecules — not automatic clinical equivalence. forum
- Repair / recovery neighbors: BPC-157, TB-500/TB4, GHK-Cu appear on the same longevity-immune boards without controlled stack data. forum
- Antimicrobial peptide adjacency: LL-37 sometimes discussed nearby for infection-theme stacks — over-stacking immune modulators is a common caution. forum
- Lifestyle co-factors: Sleep, protein intake, lower training load during illness recovery, and basic micronutrients often share credit for “resilience” wins. forum
- Caution: Multiple immune modulators without labs or a clear hypothesis is flagged as over-stacking and attribution fog. forum
- Separate annual courses (originator-adjacent pattern): Geroprotection literature often gave thymic and pineal agents as separate yearly courses rather than one mixed syringe — community practice varies. trial
- Combined-arm signal honesty: Largest mortality signals in originator elderly cohorts often sit in combined Thymalin + epithalamin arms — not clean additive proof for either alone. trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection site: Transient pain, redness, swelling, or irritation (IM or SubQ) — most common community complaint; larger multi-mg volumes can sting more. forum
- Mild systemic: Occasional headache, nausea, short-lived fatigue, restlessness, or mood notes in secondary sources. forum
- Flu-like / immune-activation window: Minority reports of mild flu-like response ~24–48 hours framed as immune activation — not universal. forum
- Energy lift or dip: Occasional temporary energy changes either direction during the course. forum
- Autoimmune caution: Active autoimmune disease or flare is treated as higher self-experiment uncertainty; immunomodulators can be double-edged without clinical supervision. forum
- Pregnancy / lactation: Listed as avoid / not researched in community protocol guides. forum
- Source / extract risk: Gray-market animal-derived thymus extracts risk contamination, endotoxin, mislabeling, and batch composition drift. forum
- Name mix-ups: Confusion with Thymogen, thymulin, TA-1, or TB-500 → wrong dose assumptions and wrong expectations. forum
- Route honesty: SubQ convenience is community practice; controlled human dose literature is IM — do not treat route as proven-equivalent. forum
- Interactions: No solid modern drug–drug interaction tables in forum charts; stacking multiple immune agents adds unknown risk. forum
- Not risk-free: Literature “well tolerated” and short courses ≠ unregulated, unmonitored, pharmaceutical-grade use. forum
- Originator “practically no side effects” claim: Repeated in Russian clinical summaries for Thymalin/Thymogen-class use — independent modern Western safety databases are essentially absent. trial
- Regulatory: Russian medicinal history ≠ FDA/EMA approval for anti-aging or general immune use elsewhere; research-chemical sales are not drug approval. trial
- Long-term immunomodulation: Multi-year repeated courses in originator narratives are not the same as a characterized Western chronic-safety package. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.